Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

Background: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results. Considering SARS-CoV-2's structural proteins and th...

Full description

Bibliographic Details
Main Authors: Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Informatics in Medicine Unlocked
Subjects:
COVID-19
CD147
ACE2
RdRp
Drug repurposing
Online Access:http://www.sciencedirect.com/science/article/pii/S2352914821000319

Internet

http://www.sciencedirect.com/science/article/pii/S2352914821000319

Similar Items